300 North Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

300 North Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$299K	Sell	2,182 -52,884	-96%	-$6.55M	1.83%	28
2015 Q1	$6.86M	Sell	55,066 -9,938	-15%	-$1.05M	1.51%	18
2014 Q4	$5.88M	Buy	65,004 +27,927	+75%	+$2.32M	1.35%	25
2014 Q3	$2.68M	Sell	37,077 -9,817	-21%	-$645K	0.71%	60
2014 Q2	$2.92M	Sell	46,894 -11,768	-20%	-$711K	0.72%	62
2014 Q1	$4M	Buy	58,662 +3,966	+7%	+$292K	1.04%	44
2013 Q4	$3.84M	Sell	54,696 -2,335	-4%	-$159K	1.07%	40
2013 Q3	$4.12M	Buy	57,031 +10,314	+22%	+$685K	0.96%	40
2013 Q2	$2.61M	Buy	+46,717	New	+$2.91M	1.01%	41

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

300 North Capital's BMRN Position: Q2 2015 in Review

300 North Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 96% in Q2 2015, selling an estimated $6.55M and leaving 2,182 shares worth $299K. The position accounts for 1.83% of the portfolio, ranked #28.

300 North Capital first reported a position in BMRN in Q2 2013 and has held it in 9 quarters since. The position peaked at $6.86M in Q1 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

300 North Capital held 2,182 shares of BioMarin Pharmaceuticals worth $299K as of Q2 2015.
300 North Capital sold 52,884 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $6.55M.
BioMarin Pharmaceuticals made up 1.83% of 300 North Capital's portfolio in Q2 2015, its #28 holding.
300 North Capital first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
300 North Capital's BioMarin Pharmaceuticals position peaked at $6.86M in Q1 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.